» Articles » PMID: 33769310

Efficacy of Adavosertib Therapy Against Anaplastic Thyroid Cancer

Overview
Specialties Endocrinology
Oncology
Date 2021 Mar 26
PMID 33769310
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Wee1 is a kinase that regulates the G2/M progression by the inhibition of CDK1, which is critical for ensuring DNA damage repair before initiation of mitotic entry. Targeting Wee1 may be a potential strategy in the treatment of anaplastic thyroid cancer, a rare but lethal disease. The therapeutic effects of adavosertib, a Wee1 inhibitor for anaplastic thyroid cancer was evaluated in this study. Adavosertib inhibited cell growth in three anaplastic thyroid cancer cell lines in a dose-dependent manner. Cell cycle analysis revealed cells were accumulated in the G2/M phase. Adavosertib induced caspase-3 activity and led to apoptosis. Adavosertib monotherapy showed significant retardation of the growth of two anaplastic thyroid cancer tumor models. The combination of adavosertib with dabrafenib and trametinib revealed strong synergism in vitro and demonstrated robust suppression of tumor growth in vivo in anaplastic thyroid cancer xenograft models with BRAFV600E mutation. The combination of adavosertib with either sorafenib or lenvatinib also demonstrated synergism in vitro and had strong inhibition of tumor growth in vivo in an anaplastic thyroid cancer xenograft model. No appreciable toxicity appeared in mice treated with either a single agent or combination treatment. Our findings suggest adavosertib holds the promise for the treatment of patients with anaplastic thyroid cancer.

Citing Articles

Targeting Ataxia Telangiectasia-Mutated and Rad3-Related for Anaplastic Thyroid Cancer.

Lin S, Hsueh C, Chen W, Chou T, Wong R Cancers (Basel). 2025; 17(3).

PMID: 39941729 PMC: 11816221. DOI: 10.3390/cancers17030359.


RBX1 regulates PKM alternative splicing to facilitate anaplastic thyroid carcinoma metastasis and aerobic glycolysis by destroying the SMAR1/HDAC6 complex.

Xu D, Yu J, Yang Y, Du Y, Lu H, Zhang S Cell Biosci. 2023; 13(1):36.

PMID: 36810109 PMC: 9945352. DOI: 10.1186/s13578-023-00987-8.


DNA Damage Response Inhibitors in Cholangiocarcinoma: Current Progress and Perspectives.

Gonul Geyik O, Anichini G, Ulukaya E, Marra F, Raggi C Cells. 2022; 11(9).

PMID: 35563769 PMC: 9101358. DOI: 10.3390/cells11091463.


Efficacy and Biomarker Analysis of Adavosertib in Differentiated Thyroid Cancer.

Lu Y, Wu M, Lee Y, Chou T, Wong R, Lin S Cancers (Basel). 2021; 13(14).

PMID: 34298699 PMC: 8306685. DOI: 10.3390/cancers13143487.

References
1.
Lindqvist A, van Zon W, Rosenthal C, Wolthuis R . Cyclin B1-Cdk1 activation continues after centrosome separation to control mitotic progression. PLoS Biol. 2007; 5(5):e123. PMC: 1858714. DOI: 10.1371/journal.pbio.0050123. View

2.
Ito T, Seyama T, Hayashi Y, Hayashi T, Dohi K, Mizuno T . Establishment of 2 human thyroid-carcinoma cell-lines (8305c, 8505c) bearing p53 gene-mutations. Int J Oncol. 2011; 4(3):583-6. DOI: 10.3892/ijo.4.3.583. View

3.
Smallridge R, Ain K, Asa S, Bible K, Brierley J, Burman K . American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2012; 22(11):1104-39. DOI: 10.1089/thy.2012.0302. View

4.
Joukov V, De Nicolo A . Aurora-PLK1 cascades as key signaling modules in the regulation of mitosis. Sci Signal. 2018; 11(543). DOI: 10.1126/scisignal.aar4195. View

5.
Robb R, Yang L, Shen C, Wolfe A, Webb A, Zhang X . Inhibiting BRAF Oncogene-Mediated Radioresistance Effectively Radiosensitizes BRAF-Mutant Thyroid Cancer Cells by Constraining DNA Double-Strand Break Repair. Clin Cancer Res. 2019; 25(15):4749-4760. PMC: 6677585. DOI: 10.1158/1078-0432.CCR-18-3625. View